🔗 Visit the ClinicalTrials.gov page for NCT02366143
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Checkpoint inhibitors in lung cancer: latest developments and clinical potential. | Ther Adv Med Oncol | 2016 | 0.96 |
| 2 | Advances in targeted and immunobased therapies for colorectal cancer in the genomic era. | Onco Targets Ther | 2016 | 0.81 |
| 3 | Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. | Invest New Drugs | 2016 | 0.80 |
| 4 | Recent Advances in Immunotherapy in Metastatic NSCLC. | Front Oncol | 2016 | 0.79 |
| 5 | Chemotherapy remains an essential element of personalized care for persons with lung cancers. | Ann Oncol | 2016 | 0.77 |
| 6 | Lung cancer in 2015: Bypassing checkpoints, overcoming resistance, and honing in on new targets. | Nat Rev Clin Oncol | 2015 | 0.76 |
| 7 | Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer? | Transl Lung Cancer Res | 2016 | 0.75 |